Rubric Capital Management (New York)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Rubric Capital Management (New York)’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-877,161	Closed	-$4.4M	–	104
2022 Q4	$4.4M	Hold	877,161	–	–	0.19%	74
2022 Q3	$11.5M	Buy	877,161 +79,573	+10%	+$1.21M	0.58%	43
2022 Q2	$10.2M	Buy	+797,588	New	+$11M	0.54%	43

Other funds holding NGM

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Rubric Capital Management (New York)'s NGM Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 877,161 shares — an estimated $4.4M sold.

Rubric Capital Management (New York) first reported a position in NGM in Q2 2022 and held it in 3 quarters. The position peaked at $11.5M in Q3 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

Rubric Capital Management (New York) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 877,161 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $4.4M.
Rubric Capital Management (New York) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Rubric Capital Management (New York)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $11.5M in Q3 2022.
122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.